NovoCureNVCR
Market Cap: $1.93B
About: NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Employees: 1,453
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
303% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $5.55M
13% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 69
11% more capital invested
Capital invested by funds: $1.43B [Q1] → $1.59B (+$164M) [Q2]
1.37% more ownership
Funds ownership: 84.99% [Q1] → 86.36% (+1.37%) [Q2]
6% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 49
1% less funds holding
Funds holding: 236 [Q1] → 233 (-3) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Wells Fargo Larry Biegelsen 76% 1-year accuracy 29 / 38 met price target | 124%upside $40 | Overweight Maintained | 26 Jul 2024 |
HC Wainwright & Co. Emily Bodnar 31% 1-year accuracy 34 / 111 met price target | 35%upside $24 | Neutral Maintained | 26 Jul 2024 |
Evercore ISI Group Vijay Kumar 93% 1-year accuracy 25 / 27 met price target | 12%upside $20 | In-Line Maintained | 2 Jul 2024 |
Financial journalist opinion
Based on 4 articles about NVCR published over the past 30 days